Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
VJHemOnc is pleased to be a media partner for the 3rd European Research Initiative on CLL (ERIC) International Meeting, New Frontiers in CLL Research, which took place on 6-8 October 2022 in Barcelona, Spain, and gathered leading experts in CLL to discuss the most exciting updates in this field. Visit ericll2022.orgto find out more about ERIC.
It's been a jam-packed morning here in Glasgow at #IMS26! 🏴
From new data to clinical practice insights, we've covered a lot of ground in #MultipleMyeloma with experts including @DrOlaLandgren, @YiLinMDPhD, @MyMKaiser, and Elena Zamagni.
Thank you to Luciano Costa (@End_myeloma) for stopping by just now to share insights from the MajesTEC-3 post hoc analysis, comparing tec-dara with dara-based triplets in R/R #MultipleMyeloma.
It was great speaking with @DrRakeshPopat this afternoon at #IMS26 to discuss the interim results from the ProMMise D study and gain insights into the CEVOLUTION trial.
Full interview coming soon to https://VJHemOnc.com 📽️ 👀
The European Research Initiative on CLL 2022 Meeting
06–08 October 2022 | Barcelona, Spain
VJHemOnc is pleased to be a media partner for the 3rd European Research Initiative on CLL (ERIC) International Meeting, New Frontiers in CLL Research, which took place on 6-8 October 2022 in Barcelona, Spain, and gathered leading experts in CLL to discuss the most exciting updates in this field. Visit ericll2022.orgto find out more about ERIC.
It's been a jam-packed morning here in Glasgow at #IMS26! 🏴
From new data to clinical practice insights, we've covered a lot of ground in #MultipleMyeloma with experts including @DrOlaLandgren, @YiLinMDPhD, @MyMKaiser, and Elena Zamagni.
Thank you to Luciano Costa (@End_myeloma) for stopping by just now to share insights from the MajesTEC-3 post hoc analysis, comparing tec-dara with dara-based triplets in R/R #MultipleMyeloma.
It was great speaking with @DrRakeshPopat this afternoon at #IMS26 to discuss the interim results from the ProMMise D study and gain insights into the CEVOLUTION trial.
Full interview coming soon to https://VJHemOnc.com 📽️ 👀
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.